Business Wire

SES Market Update in Context of Moody’s Ratings Press Release

Share

SES S.A. has taken note of Moody’s Ratings Press Release today with regards to SES and is providing a market update ahead of its Full Year 2024 financial results announcement on 26 February 2025.

SES expects Full Year 2024 Results(1) to be better-than-expected with Revenue at the top end of the financial outlook range (€1,940-2,000 million)(2) and Adjusted EBITDA above the outlook range (€950-1,000 million)(2).

The proposed acquisition of Intelsat is on track to close during H2 2025. SES expects to reconfirm all financial targets for the combined company (pre-IRIS2) published in the transaction announcement in April 2024, including low- to mid-single digit average annual growth in Revenue for 2024-2028E, mid-single digit average annual growth in Adjusted EBITDA for 2024-2028E, and strong Free Cash Flow generation. SES remains committed to maintaining Investment Grade metrics.

SES management looks forward to announcing its Full Year 2024 Results and discussing these, as well as its views on the outlook for the sector with market participants on 26 February 2025.

Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >
Visit the Media Gallery >

_____________________________
1) The financial information disclosed in today’s announcement remains subject to audit.
2) Full Year 2024 outlook assumes €/$ FX rate of €1 = $1.09, nominal satellite health, and nominal launch schedule.


About SES

SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous orbit fleet and medium earth orbit (GEO-MEO) constellation of satellites, offering a combination of global coverage and high performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

Forward looking statements

This communication contains forward-looking statements. Generally, the words “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “contemplate,” “predict,” “forecast,” “likely,” “believe,” “target,” “will,” “could,” “would,” “should,” “potential,” “may” and similar expressions or their negative, may, but are not necessary to, identify forward-looking statements. Such forward-looking statements, including those regarding the timing and consummation of the transaction described herein, involve risks and uncertainties. SES’s and Intelsat’s experience and results may differ materially from the experience and results anticipated in such statements. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but not limited to, the following factors: the risk that the conditions to the closing of the transaction are not satisfied, including the risk that required approvals of the transaction from the shareholders of Intelsat or from regulators are not obtained; litigation relating to the transaction; uncertainties as to the timing of the consummation of the transaction and the ability of each party to consummate the transaction; risks that the proposed transaction disrupts the current plans or operations of SES or Intelsat; the ability of SES and Intelsat to retain and hire key personnel; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to relationships with customers, suppliers, distributors and other business partners resulting from the announcement or completion of the transaction; the combined company’s ability to achieve the synergies expected from the transaction, as well as delays, challenges and expenses associated with integrating the combined company’s existing businesses; the impact of overall industry and general economic conditions, including inflation, interest rates and related monetary policy by governments in response to inflation; geopolitical events, and regulatory, economic and other risks associated therewith; and continued uncertainty around the macroeconomy. Other factors that might cause such a difference include those discussed in the prospectus on Form F-4 to be filed in connection with the proposed transaction. The forward-looking statements included in this communication are made only as of the date hereof and, except as required by federal securities laws and rules and regulations of the SEC, SES and Intelsat undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional Information and Where to Find It

In connection with the proposed transaction, SES intends to file with the SEC a registration statement on Form F-4 that also constitutes a prospectus of SES. SES also plans to file other relevant documents with the SEC regarding the proposed transaction. No offer of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROSPECTUS AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and shareholders will be able to obtain free copies of these documents (if and when available), and other documents containing important information about SES and Intelsat, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by SES will be available free of charge on SES’s website at www.ses.com or by contacting SES’s Investor Relations Department by email at ir@ses.com. Copies of the documents filed with the SEC by Intelsat will be available free of charge on Intelsat’s website at www.intelsat.com or by contacting Intelsat’s Investor Relations Department by email at investor.relations@intelsat.com.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. No offer of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218046664/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab20.2.2025 17:45:00 CET | Press release

Post-hoc analyses at ECCO 2025 build on pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) which has previously demonstrated superior efficacy of subcutaneous (SC) infliximab (CT-P13 SC) over placebo in moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC)1,2New data highlights the effectiveness of SC infliximab in achieving endoscopic-histologic remission in UC and clinical and endoscopic improvement in CD across all disease locations3,4Further insights on rapid clinical recapture following dose escalation of SC infliximab after loss of response and long-term drug persistence in CD regardless of anti-drug antibodies (ADA) occurrence highlights the robustness of SC infliximab in IBD management5,6 Celltrion announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory

NTT DATA Launches Smart AI Agent™ to Accelerate Generative AI Adoption and Drive $2 Billion in Revenue by 202720.2.2025 16:33:00 CET | Press release

Next-generation AI tool will enhance operational efficiency, address global talent shortages, and empower businesses with smarter automation. NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agent™. This advanced AI tool is a cornerstone of the company’s strategy to accelerate the adoption of Generative AI, with an estimated $2 billion in revenue that we aim to achieve from Smart AI Agent™-related business by 2027. The Smart AI Agent™ autonomously extracts, organizes, and executes tasks in response to user instructions, complementing existing workforces and streamlining time-consuming processes. By enhancing efficiency across industries, the Smart AI Agent™ enables businesses to rapidly evaluate and deploy Generative AI applications, optimizing workflows and driving greater productivity. Yutaka Sasaki, President and CEO, NTT DATA, said: “The launch of our Smart AI Agent™ is a direct response to the grow

New global guideline published on managing fungal infections caused by Candida20.2.2025 16:15:00 CET | Press release

For Trade and Medical Media Only A new global guideline for the diagnosis and treatment of Candidainfections was recently published in Lancet Infectious Diseases1. This guideline sets out new standards for managing fungal infections, which affect millions of people worldwide every year. The global guideline was developed by a team of more than 100 experts spanning 35 countries and led by Professor Dr. Oliver A. Cornely and Dr. Rosanne Sprute from University Hospital Cologne. One year following the European Medical Association (EMA)2 approval, rezafungin ▼3 has been included in the guideline, along with other echinocandins, as a strongly recommended first line therapy option for the treatment of candidaemia. Echinocandins, including rezafungin, are preferred for all forms of invasive candidiasis, excluding CNS and ocular infections, due to their broad antifungal activity and favourable safety profile. The new guideline, which took four years to develop, contains recommendations for clin

SiMa.ai and HTEC Strengthen Strategic Partnership to Advance Premium ML System-on-Chip Solutions20.2.2025 16:08:00 CET | Press release

HTEC, a global digital engineering services firm, is pleased to announce a partnership extension with SiMa.ai, the software-centric, embedded edge machine learning system-on-chip (MLSoC) company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220864540/en/ HTEC announces partnership extension with SiMa.ai, an embedded edge machine learning system-on-chip company. (Graphic: Business Wire) During a successful five-year collaboration, SiMa.ai and HTEC built an ML compiler, system drivers, and other complex AI-powered software tools to support SiMa.ai’s edge AI platform. SiMa.ai also leveraged HTEC’s AI- and ML-driven engineering and chip optimization expertise to enhance its purpose-built MLSoC™. Now, HTEC will support SiMa.ai’s strategic initiatives and help streamline the delivery of SiMa.ai solutions built on its cutting-edge ONE Platform for Edge AI, further enhancing the company’s hardware and software. “Collaborating w

ClickHouse Announces BYOC (Bring Your Own Cloud) on AWS20.2.2025 15:00:00 CET | Press release

Bringing the power of the fastest real-time analytical database to customer VPCs As enterprises look to modernize and adopt cloud-native architectures, they must still comply with existing security mandates and geographic regulations. This becomes especially challenging with cloud-based database services, where any data leaving the enterprise Virtual Private Cloud (VPC) requires thorough security review. These considerations are critical for organizations in regulated industries or those handling sensitive customer data. ClickHouse BYOC was built to address this very challenge. It allows organizations to adopt unique capabilities of the fully-managed ClickHouse Cloud service, a leading real-time analytical database, while maintaining full ownership and control of their data within their VPC. In ClickHouse BYOC architecture, the data plane consisting of storage and compute resources resides in the customer VPC, which ensures that customers are able to adhere to data residency and govern

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye